The purpose of this study was to evaluate the effectiveness of a pharmacological compound called FP-1201-lyo (recombinant human interferon IFN beta-1a) on the reduction of leakage from the lungs in a disease known as ARDS (Acute Respiratory Distress Syndrome). ARDS is a potentially life threatening condition which causes leaking of fluid from the lungs, inflammation and respiratory failure. The patients were recruited whilst patients on the Adult Intensive Care Unit (AICU).